ReviewWorld journal of gastroenterology2008
Updates on treatment of irritable bowel syndrome.
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.World journal of gastroenterology · 2015Pooled it
- Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: a randomized wait-list controlled trial.International journal of behavioral medicine · 2013Trial
- Probiotic treatment of irritable bowel syndrome in children.German medical science : GMS e-journal · 2010Trial
- A double-blind randomized clinical trial ofResearch in pharmaceutical sciences · 2023Article
- The potential influence of melatonin on mitochondrial quality control: a review.Frontiers in pharmacology · 2023Review
- Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.Food science and biotechnology · 2020Article
- Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome.Scientific reports · 2017Article
- Molecular and functional diversity of GABA-A receptors in the enteric nervous system of the mouse colon.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Melatonin for the treatment of irritable bowel syndrome.World journal of gastroenterology · 2014Review
- Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity.Brain research · 2010Article
- An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium.Gastroenterology & hepatology · 2010Article
- Irritable bowel syndrome: are complementary and alternative medicine treatments useful?Canadian family physician Medecin de famille canadien · 2009Article
- State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008.World journal of gastroenterology · 2008Article
- Saccharomyces cerevisiae for abdominal pain and discomfort in irritable bowel syndrome patients.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder characterized by abdominal pain and discomfort in association with altered bowel habits. It is estimated to affect 10%-15% of the Western population, and has a large impact on quality of life and (in)direct healthcare costs. IBS is a multifactorial disorder involving dysregulation within the brain-gut axis, and it is frequently associated with gastrointestinal motor and sensory dysfunction, enteric and central nervous system irregularities, neuroimmune dysregulation, and post-infectious inflammation. As with other functional medical disorders, the treatment for IBS can be challenging. Conventional therapy for those with moderate to severe symptoms is largely unsatisfactory, and the development of new and effective drugs is made difficult by the complex pathogenesis, variety of symptoms, and lack of objective clinical findings that are the hallmark of this disorder. Fortunately, research advances over the past several decades have provided insight into potential mechanisms responsible for the pathogenesis of IBS, and have led to the development of several promising pharmaceutical agents. In recent years there has been much publicity over several of these new IBS medications (alosetron and tegaserod) because of their reported association with ischemic colitis and cardiovascular disease. While these agents remain available for use under restricted prescribing programs, this highlights the need for continued development of safe and effective medication for IBS. This article provides a physiologically-based overview of recently developed and frequently employed pharmaceutical agents used to treat IBS, and discusses some non-pharmaceutical options that may be beneficial in this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.